<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738580</url>
  </required_header>
  <id_info>
    <org_study_id>1512-VLC-066-EB</org_study_id>
    <nct_id>NCT02738580</nct_id>
  </id_info>
  <brief_title>Follicular Steroid Genesis in Controlled Ovarian Stimulation</brief_title>
  <acronym>ESTEFOL</acronym>
  <official_title>Analysis of Follicular Steroid Synthesis During Controlled Ovarian Stimulation With Recombinant FSH vs HMG in GnRH Antagonist Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum concentrations of the different hormones involved in follicular steroid genesis during
      a cycle of controlled ovarian stimulation with recombinant FSH or HMG will be compared in
      this study. Serum Progesterone (P) levels at the end of Controlled Ovarian Stimulation (i.e.
      the day of triggering) have been related to cycle outcome, in terms of ongoing pregnancy and
      live birth rates. Large cohort studies show that P levels above a certain threshold are
      associated with poorer cycle outcome. The mechanisms behind P elevation are not well
      understood yet. It has been shown that P levels are positively related to ovarian response
      and to the dose of FSH given during COS. Furthermore, it has been well documented that P
      levels at the end of stimulation are significantly higher when recombinant (r) FSH is used
      for COS when compared to HMG, either in a GnRH agonist long protocol or in a GnRH antagonist
      protocol. Some authors suggest that this finding is explained by the fact that COS with rFSH
      provides a higher oocyte yield than when hMG is given, so the higher P levels observed would
      be explained by the larger number of follicles developed when rFSH is used. On the other
      hand, other authors explain this event by a different follicular esteroidogenesis when HMG is
      used for COS compared to rFSH The hypotheisis behind this assumption is that rFSH enhances P
      synthesis from its precursor pregnenolone in the granulosa cells. This P is unable to be
      further metabolized into androgens because of the lack of 17-20 lyase in the human granulosa
      cells, and therefore is delivered into circulation. On the other hand, when HMG is given for
      COS, the âˆ†4 pathway is promoted, and pregnenolone will be catabolized in to
      Dehidroepiandrostenodione (DHEA), in the theca cells, and this one to Androstenodione, which
      will be finally aromatized in to estrogens. This mechanism will explain the lower P and
      higher E2 levels observed in HMG cycles in comparison to rFSH cycles.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Actual">June 15, 2018</completion_date>
  <primary_completion_date type="Actual">June 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SERUM PROGSTERONE CONCENTRATION</measure>
    <time_frame>21 days</time_frame>
    <description>Compare hormonal blood serum concentrations of progesterone during ovarian stimulation implied in follicular steroidogenesis during a cycle of Controlled Ovarian Stimulation with either r-FSH or HP-HMG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OVARIAN RESPONSE</measure>
    <time_frame>21 days</time_frame>
    <description>NUMBER OF FOLICLES REACHED AND PUNCTURED AFTER CONTROLED OVARIAN STIMULATION</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Infertility</condition>
  <condition>Controlled Ovarian Hyperstimulation</condition>
  <arm_group>
    <arm_group_label>rFSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HP-HMG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COS with GnRH antagonists and rFSH</intervention_name>
    <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
    <arm_group_label>rFSH</arm_group_label>
    <other_name>GnRH antagonists and rFSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COS with GnRH antagonists and HP-HMG</intervention_name>
    <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
    <arm_group_label>HP-HMG</arm_group_label>
    <other_name>GnRH antagonists and HP-HMG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good physical and psychological condition

          -  Normal menstrual cycle (25-35 days)

          -  Normal ovarian reserve defined by serum ANH010-30 pMol/L

          -  All other criteria to fulfill by oocyte donors

        Exclusion Criteria:

          -  Kidney failure

          -  Ovarian Polyquistic syndrome

          -  Any systemic or metabolic disfunction that counter indicates the use of gonadotrophins

          -  Any other reason that involves exclusion of the oocyte donation program
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernesto Bosch, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI VALENCIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>December 13, 2019</results_first_submitted>
  <results_first_submitted_qc>February 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02738580/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rFSH</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
COS with GnRH antagonists and rFSH: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
        </group>
        <group group_id="P2">
          <title>HP-HMG</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
COS with GnRH antagonists and HP-HMG: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56">56 patients were assigned to this arms.</participants>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">3 cycles cancelled due to por response to stimullation.
1 cycle cancelled due to SAE.</participants>
                <participants group_id="P2" count="52">2 cycles cancelled due to por response to stimullation
1 patient withdrawal
1 excluded</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>EXCLUDED FROM DONNOR PROGRAM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rFSH</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
COS with GnRH antagonists and rFSH: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
        </group>
        <group group_id="B2">
          <title>HP-HMG</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
COS with GnRH antagonists and HP-HMG: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="56"/>
                    <count group_id="B3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="56"/>
                    <count group_id="B3" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SERUM PROGSTERONE CONCENTRATION</title>
        <description>Compare hormonal blood serum concentrations of progesterone during ovarian stimulation implied in follicular steroidogenesis during a cycle of Controlled Ovarian Stimulation with either r-FSH or HP-HMG.</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rFSH</title>
            <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
COS with GnRH antagonists and rFSH: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
          </group>
          <group group_id="O2">
            <title>HP-HMG</title>
            <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
COS with GnRH antagonists and HP-HMG: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
          </group>
        </group_list>
        <measure>
          <title>SERUM PROGSTERONE CONCENTRATION</title>
          <description>Compare hormonal blood serum concentrations of progesterone during ovarian stimulation implied in follicular steroidogenesis during a cycle of Controlled Ovarian Stimulation with either r-FSH or HP-HMG.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.22" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.19" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The proportion of patients with elevated Progesterone on last day of stimulation(&gt;1.5 ng/mL) was compared between both groups using the Chi-square test.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OVARIAN RESPONSE</title>
        <description>NUMBER OF FOLICLES REACHED AND PUNCTURED AFTER CONTROLED OVARIAN STIMULATION</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rFSH</title>
            <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
COS with GnRH antagonists and rFSH: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
          </group>
          <group group_id="O2">
            <title>HP-HMG</title>
            <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
COS with GnRH antagonists and HP-HMG: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
          </group>
        </group_list>
        <measure>
          <title>OVARIAN RESPONSE</title>
          <description>NUMBER OF FOLICLES REACHED AND PUNCTURED AFTER CONTROLED OVARIAN STIMULATION</description>
          <units>folicles</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O2" value="17.5" lower_limit="9.6" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.49</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 Days</time_frame>
      <desc>Coagulation panel alteration.</desc>
      <group_list>
        <group group_id="E1">
          <title>rFSH</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
COS with GnRH antagonists and rFSH: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.</description>
        </group>
        <group group_id="E2">
          <title>HP-HMG</title>
          <description>Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
COS with GnRH antagonists and HP-HMG: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Vitamin K Deficiency</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>COAGULATION PANEL ALTERATION</sub_title>
                <description>PT: 15,4 seg; INR: 1,3; Quick Index: 69%; TTPA: 38 seg. Hemmatic parameters at minimum normal limits She was reffered to hemathologist department. There was not more information about patient since january 2018.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. ERNESTO BOSCH</name_or_title>
      <organization>IVIValencia</organization>
      <phone>+34 963050900</phone>
      <email>Ernesto.Bosch@ivirma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

